A critical advance in cancer investigation is occurring with the use of nanobodies to reactivate dysfunctional p53. This essential malignant inhibitor protein is frequently disabled in various forms of malignancies, https://bookmarkleader.com/story21983854/mini-antibodies-revive-p53-a-potential-pathway-for-malignant-therapy